Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Prices Senior Notes

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today priced its previously announced senior notes being issued to partially fund its $3.5 billion purchase of Phadia.

In total, the company is offering $2.1 billion in senior notes — $1 billion worth of 2.25 percent notes due 2016 at an issue price of 99.826 percent of the principal amount, and $1.1 billion of 3.6 percent notes due in 2021 at an issue price of 99.809 percent of the principal amount.

The issuance of the notes is expected to close on Aug. 16 and will pay interest on a semi-annual basis.

Ratings firm Fitch yesterday assigned an "A-" rating to the notes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.